JUN and Miyoshi myopathy: HDACis, comprising trichostatin A (TSA), valproic acid (VPA), vorinostat (SAHA), and LBH589, inhibit the transcription of both Fra-1 and c-Jun, and so decrease c-Jun: Fra-1 heterodimer production [76], which may justify their anti-MM efficacy.